![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1510694
ºÏ¹ÌÀÇ ½ÉÀå ÀÌ½Ä ½ÃÀå : Áö¿ªº° ºÐ¼® - ¼ö¼úÀ¯Çüº°, À¯Çüº°, ÃÖÁ¾ »ç¿ëÀÚº° ¿¹Ãø(-2030³â)North America Heart Transplant Market Forecast to 2030 - Regional Analysis - by Surgery Type, Type, and End User |
ºÏ¹ÌÀÇ ½ÉÀå ÀÌ½Ä ½ÃÀåÀº 2022³â 72¾ï 5,210¸¸ ´Þ·¯¿¡¼ 2030³â¿¡´Â 171¾ï 9,272¸¸ ´Þ·¯·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¿¹Ãø±â°£ µ¿¾È º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR)Àº 11.4%·Î ÃßÁ¤µË´Ï´Ù.
ÀÌ½Ä ¼ö¼ú¿¡¼ AIÀÇ È°¿ëÀÌ ºÏ¹ÌÀÇ ½ÉÀå ÀÌ½Ä ½ÃÀåÀ» µÞ¹Þħ
ÀΰøÁö´É(AI)¿¡ µÞ¹ÞħµÈ µ¶ÀÚ ¼³°è ½Ã½ºÅÛÀº ½ÉÀå ÀÌ½Ä ÈÄ ¼÷ÁÖ °ÅºÎ ¹ÝÀÀÀÇ Á¶±â ¡ÈÄ¿Í ÁßÁõµµÀÇ °ËÃâÀ» ¿ëÀÌÇÏ°Ô ÇÕ´Ï´Ù. ½É±Ù ³»¸· »ý°Ë(EMB) ½ºÅ©¸®´×Àº ½ÉÀå ÀÌ½Ä ÈÄ µ¿Á¾ ÀÌ½Ä °ÅºÎ ¹ÝÀÀÀ» È®ÀÎÇϴ ǥÁØ Ä¡·á¸¦ ÀǹÌÇÕ´Ï´Ù. 2022³â¿¡´Â ½ÉÀå °ÅºÎ ¹ÝÀÀ Æò°¡ ½Å°æ ÃßÁ¤ ÀåÄ¡(CRANE)·Î ¾Ë·ÁÁø »õ·Î¿î AI ½Ã½ºÅÛÀÌ ¼³°èµÇ¾î ½Å¼ÓÇϰí Á¤È®ÇÑ Áø´ÜÀ» À§ÇØ ÀÇÇÐÀû Æò°¡¿Í ÇÔ²² »ç¿ëÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. CRANEÀº ¶ÇÇÑ ¼÷ÁÖ ½Åü¿¡¼ ½ÉÀå °ÅºÎ ¹ÝÀÀÀÇ À¯¹«¿Í ÁßÁõµµ¿¡ ´ëÇÑ Â÷À̸¦ ÁÙÀÏ ¼ö ÀÖ½À´Ï´Ù. EMB¿¡¼ ¾òÀº ±â°¡ Çȼ¿ÀÇ Àüü ½½¶óÀ̵å À̹ÌÁö¸¦ ÀÚµ¿ Æò°¡ÇÏ´Â µö·¯´× ±â¹Ý AI ½Ã½ºÅÛÀÔ´Ï´Ù. 2020³â ¹Ì±¹ ±¹¸³À§»ý¿¬±¸¼Ò´Â ½ÉÀå À̽Ŀ¡ ÀÖ¾î¼ AIÀÇ ´É·Â ޱ¸¿¡ ±âÃÊÇÑ ¿¬±¸¿¡ 320¸¸ ´Þ·¯¸¦ Á¶¼ºÇß½À´Ï´Ù. ÀÌ º¸Á¶±ÝÀ» ÅëÇØ Æç·¼¸¸ Àǰú´ëÇÐ(Ææ½Çº£´Ï¾Æ ´ëÇÐ), ÄÉÀ̽º ¿þ½ºÅÏ ¸®Àúºê ´ëÇÐ, Ŭ¸®ºí·£µå Ŭ¸®´Ð, ½Ã´õ½º »çÀ̳ªÀÌ ¸ÞµðÄà ¼¾ÅÍÀÇ ¿¬±¸ÀÚµéÀº »õ·Î¿î ½ÉÀå °ÅºÎ ¹ÝÀÀÀÇ ¿øÀΰú ±× ´ëó¹ýÀ» Á¶»çÇÏ´Â °ÍÀ» ¸ñÇ¥·Î Çß½À´Ï´Ù. ±×µéÀº AI¸¦ »ç¿ëÇÏ¿© ½ÉÀå »ý°Ë Á¶Á÷ À̹ÌÁö¸¦ ºÐ¼®ÇÏ°í ½Å»ý ½ÉÀå °ÅºÎ ¹ÝÀÀ¿¡ Áß¿äÇÑ ¿ªÇÒÀ»ÇÏ´Â ¸é¿ª ¼¼Æ÷ÀÇ À¯ÇüÀ» ¹ß°ßÇß½À´Ï´Ù. µû¶ó¼ ½ÉÀå ÀÌ½Ä ÀýÂ÷¿¡¼ AIÀÇ Ã¤ÅÃÀº ÇâÈÄ ¸î ³âµ¿¾È ½ÃÀå¿¡ »õ·Î¿î µ¿ÇâÀ» °¡Á®¿Ã °¡´É¼ºÀÌ ³ô½À´Ï´Ù.
ºÏ¹ÌÀÇ ½ÉÀå ÀÌ½Ä ½ÃÀå °³¿ä
ºÏ¹ÌÀÇ ½ÉÀå ÀÌ½Ä ½ÃÀåÀº ¹Ì±¹, ij³ª´Ù, ¸ß½ÃÄÚ·Î ±¸ºÐµË´Ï´Ù. ºÏ¹Ì´Â 2022³â¿¡ °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇϸç, ½ÃÀå ¼ºÀåÀÇ ¹è°æ¿¡´Â ³ëÀÎ Àα¸ Áõ°¡, ½ÉÇ÷°ü Áúȯ À¯Çà ¹× ½ÉºÎÀü ȯÀÚ Áõ°¡°¡ ÀÖ½À´Ï´Ù. ¸¸¼º ½ÅÀ庴 Áõ°¡¿Í ³ëÀÎ Àα¸ Áõ°¡´Â ¹Ì±¹¿¡¼ ½ÉÀå ÀÌ½Ä ½ÃÀåÀÇ ¼ºÀå¿¡ ±â¿©ÇÏ´Â ÁÖ¿ä ¿äÀÎÀÔ´Ï´Ù. ¹Ì±¹ ½ÉÀåÇùȸ(American Heart Association Inc.)ÀÇ µ¥ÀÌÅÍ¿¡ µû¸£¸é, ¹Ì±¹¿¡¼´Â ¸Å³â 100¸¸ ¸íÀÇ ½ÉºÎÀü ȯÀÚ°¡ »õ·Ó°Ô µî·ÏµÇ¾î 2030³â±îÁö 800¸¸¸í ÀÌ»óÀÌ ½ÉºÎÀüÀ¸·Î °íÅë¹ÞÀ» °ÍÀ¸·Î ÃßÁ¤µÇ°í ÀÖ½À´Ï´Ù. º¸°Ç¿¬±¸Á¶¼º±â±¸¿¡ µû¸£¸é 2021³â¿¡´Â ¹Ì±¹¿¡¼ - 555,000¸íÀÌ ½ÉºÎÀüÀÇ Ãʱ⠴ܰè·Î Áø´ÜµÇ¾ú½À´Ï´Ù. ½ÉÇ÷°ü Áúȯ(CVD)Àº ÀϹÝÀûÀ¸·Î ½ÉºÎÀü°ú ¸»±â ½ÉÀå ÁúȯÀ¸·Î À̾îÁö¹Ç·Î ½ÉÀå À̽Ŀ¡ ´ëÇÑ ¼ö¿ä°¡ ³ô¾ÆÁý´Ï´Ù.
¹Ì±¹ ½ÄǰÀǾ౹(FDA)Àº ´Ù¾çÇÑ ½ÉÀå ÀÌ½Ä ¼ö¼ú°ú Á¦Ç°À» ½ÂÀÎÇϰí ÀÖ½À´Ï´Ù. °Ô´Ù°¡ ´ë±â¾÷ÀÇ Á¸Àç°¡ ÀÌ ³ª¶ó ½ÃÀå¿¡ ÀÌÀÍÀ» °¡Á®¿É´Ï´Ù. 2022³â 4¿ù, TransMedics Group, Inc.´Â OCS HeartÀÇ ½ÃÆÇ Àü FDA ½ÂÀÎÀ» ¹Þ¾Ò½À´Ï´Ù.
ºÏ¹ÌÀÇ ½ÉÀå ÀÌ½Ä ½ÃÀå : ¼öÀͰú ¿¹Ãø(-2030³â)(±Ý¾×)
ºÏ¹ÌÀÇ ½ÉÀå ÀÌ½Ä ½ÃÀåÀÇ ¼¼ºÐÈ
ºÏ¹ÌÀÇ ½ÉÀå ÀÌ½Ä ½ÃÀåÀº ¼ö¼ú À¯Çü, À¯Çü, ÃÖÁ¾ »ç¿ëÀÚ, ±¹°¡·Î ±¸ºÐµË´Ï´Ù.
¼ö¼ú À¯Çüº°·Î ºÏ¹ÌÀÇ ½ÉÀå ÀÌ½Ä ½ÃÀåÀº µ¿¼Ò¼º ½ÉÀå À̽İú À̼Ҽº ½ÉÀå À̽ÄÀ¸·Î À̺е˴ϴÙ. 2022³â ºÏ¹ÌÀÇ ½ÉÀå ÀÌ½Ä ½ÃÀå¿¡¼´Â µ¿¼Ò¼º ½ÉÀå ÀÌ½Ä ºÐ¾ß°¡ Å« Á¡À¯À²À» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù.
À¯Çüº°·Î ºÏ¹ÌÀÇ ½ÉÀå ÀÌ½Ä ½ÃÀåÀº ±âÁõÀÚ ¶óÀÌºê ½ÉÀå°ú Àΰø ½ÉÀåÀ¸·Î À̺е˴ϴÙ. 2022³â ºÏ¹ÌÀÇ ½ÉÀå ÀÌ½Ä ½ÃÀå¿¡¼´Â ±âÁõÀÚ ¶óÀÌºê ½ÉÀå ºÐ¾ß°¡ Å« Á¡À¯À²À» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Àΰø ½ÉÀå ºÎ¹®Àº ½É½Ç º¸Á¶ ÀåÄ¡¿Í Àüü Àΰø ½ÉÀåÀ¸·Î ºÐ·ùµË´Ï´Ù.
ÃÖÁ¾ »ç¿ëÀÚº°·Î ºÏ¹ÌÀÇ ½ÉÀå ÀÌ½Ä ½ÃÀåÀº º´¿ø, ½ÉÀå ¼¾ÅÍ µîÀ¸·Î ±¸ºÐµË´Ï´Ù. 2022³â ºÏ¹ÌÀÇ ½ÉÀå ÀÌ½Ä ½ÃÀå¿¡¼´Â º´¿ø ºÎ¹®ÀÌ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇÕ´Ï´Ù.
±¹°¡º°·Î ºÏ¹ÌÀÇ ½ÉÀå ÀÌ½Ä ½ÃÀåÀº ¹Ì±¹, ij³ª´Ù, ¸ß½ÃÄÚ·Î ±¸ºÐµË´Ï´Ù. ¹Ì±¹Àº 2022³â ºÏ¹ÌÀÇ ½ÉÀå ÀÌ½Ä ½ÃÀåÀ» µ¶Á¡Çß½À´Ï´Ù.
Terumo Corp, Evaheart Inc, Abbott Laboratories, SynCardia Systems LLC, BiVACOR Inc, BioVentrix Inc, Berlin Heart GmbH, LivaNova Plc, Jarvik Heart Inc, Calon Cardio - Technology Ltd´Â ºÏ¹ÌÀÇ ½ÉÀå ÀÌ½Ä ½ÃÀå¿¡¼ »ç¾÷À» Àü°³Çϰí ÀÖ½À´Ï´Ù. ±â¾÷ÀÔ´Ï´Ù.
¸ñÂ÷
The North America heart transplant market is expected to grow from US$ 7,252.10 million in 2022 to US$ 17,192.72 million by 2030. It is estimated to grow at a CAGR of 11.4% from 2022 to 2030.
Use of AI in Transplantation Procedures Fuels North America Heart Transplant Market
A uniquely designed system backed by artificial intelligence (AI) facilitates the detection of early signs and seriousness of the host rejection post-heart transplantation. The endomyocardial biopsy (EMB) screening signifies the standard of care for identifying allograft rejections after a heart transplant. In 2022, a new AI system was designed known as the Cardiac Rejection Assessment Neural Estimator (CRANE), which can be used in tandem with medical assessments for rapid and precise diagnosis. CRANE also helps reduce differences regarding the presence and severity of heart rejection in the host body. It is a deep learning-based AI system for the automated assessment of gigapixel whole-slide images obtained from EMBs. In 2020, the National Institute of Health granted US$ 3.2 million to studies based on the exploration of the capabilities of AI in heart transplants. With this grant, researchers from Perelman School of Medicine (the University of Pennsylvania), Case Western Reserve University, Cleveland Clinic, and Cedars-Sinai Medical Center aimed to study what causes the rejection of a new heart and how to manage it. They used AI to analyze cardiac biopsy tissue images, finding the types of immune cells that play an instrumental role in new heart rejection. Thus, the adoption of AI in heart transplantation procedures is likely to bring new trends in the market in the coming years.
North America Heart Transplant Market Overview
The heart transplant market in North America is segmented into the US, Canada, and Mexico. North America accounted for the largest market share in 2022, and the market growth can be attributed to an upsurge in the geriatric population, the prevalence of cardiovascular diseases, and an increase in heart failure cases. The increasing incidences of chronic kidney diseases and the rising geriatric population are the key factors contributing to the heart transplant market growth in the US. According to data provided by the American Heart Association Inc., ~1 million new heart failure cases are registered annually in the US, and more than 8 million people are estimated to suffer from heart failure by 2030. As per the Health Research Funding Organization, ~555,000 people were diagnosed with the beginning stages of heart failure in the US in 2021. Cardiovascular diseases (CVDs) generally lead to heart failure or terminal heart disease, which bolsters the demand for heart transplants.
The US Food and Drug Administration (FDA) is increasingly approving various heart transplant procedures and products. In addition, the presence of major companies benefits the market in this country. In April 2022, TransMedics Group, Inc. received premarket FDA approval for its OCS Heart.
North America Heart Transplant Market Revenue and Forecast to 2030 (US$ Million)
North America Heart Transplant Market Segmentation
The North America heart transplant market is segmented into surgery type, type, end user, and country.
Based on surgery type, the North America heart transplant market is bifurcated into orthotopic heart transplantation and heterotopic heart transplantation. The orthotopic heart transplantation segment held a larger share of the North America heart transplant market in 2022.
In terms of type, the North America heart transplant market is bifurcated into donor live heart and artificial heart. The donor live heart segment held a larger share of the North America heart transplant market in 2022. Further, artificial heart segment is categorized into ventricular assisted device and total artificial heart.
Based on end user, the North America heart transplant market is segmented into hospitals, cardiac centers, and others. The hospitals segment held the largest share of the North America heart transplant market in 2022.
Based on country, the North America heart transplant market is segmented into the US, Canada, and Mexico. The US dominated the North America heart transplant market in 2022.
Terumo Corp, Evaheart Inc, Abbott Laboratories, SynCardia Systems LLC, BiVACOR Inc, BioVentrix Inc, Berlin Heart GmbH, LivaNova Plc, Jarvik Heart Inc, and Calon Cardio-Technology Ltd are some of the leading companies operating in the North America heart transplant market.
Table of Content